Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 99

Similar articles for PubMed (Select 19595612)

1.

CD40 and autoimmunity: the dark side of a great activator.

Peters AL, Stunz LL, Bishop GA.

Semin Immunol. 2009 Oct;21(5):293-300. doi: 10.1016/j.smim.2009.05.012. Review.

2.

The role of CD40-CD154 interactions in autoimmunity and the benefit of disrupting this pathway.

Toubi E, Shoenfeld Y.

Autoimmunity. 2004 Sep-Nov;37(6-7):457-64. Review.

PMID:
15621572
3.

The role of CD40-CD154 interaction in cell immunoregulation.

Xu Y, Song G.

J Biomed Sci. 2004 Jul-Aug;11(4):426-38. Review.

PMID:
15153777
4.

Costimulatory molecule CD154 in systemic lupus erythematosus and rheumatoid arthritis. Therapeutic perspectives.

Dejica DI, Manea EM.

Roum Arch Microbiol Immunol. 2006 Jan-Jun;65(1-2):66-74. Review.

PMID:
17877113
5.
6.
7.
8.

T cells interact with T cells via CD40-CD154 to promote autoimmunity in type 1 diabetes.

Baker RL, Mallevaey T, Gapin L, Haskins K.

Eur J Immunol. 2012 Mar;42(3):672-80. doi: 10.1002/eji.201142071.

9.

Therapeutic interventions targeting CD40L (CD154) and CD40: the opportunities and challenges.

Law CL, Grewal IS.

Adv Exp Med Biol. 2009;647:8-36. doi: 10.1007/978-0-387-89520-8_2. Review.

PMID:
19760064
10.

Regulation of CD40 ligand expression in systemic lupus erythematosus.

Crow MK, Kirou KA.

Curr Opin Rheumatol. 2001 Sep;13(5):361-9. Review.

PMID:
11604589
11.

Immunotherapy targeting the CD40/CD154 costimulatory pathway for treatment of autoimmune disease.

Howard LM, Miller SD.

Autoimmunity. 2004 Aug;37(5):411-8. Review.

PMID:
15621565
12.

The CD40/CD154 receptor/ligand dyad.

Schönbeck U, Libby P.

Cell Mol Life Sci. 2001 Jan;58(1):4-43. Review.

PMID:
11229815
13.

CD40 glycoforms and TNF-receptors 1 and 2 in the formation of CD40 receptor(s) in autoimmunity.

Vaitaitis GM, Wagner DH Jr.

Mol Immunol. 2010 Aug;47(14):2303-13. doi: 10.1016/j.molimm.2010.05.288. Epub 2010 Jun 19.

14.

Dendritic cell longevity and T cell persistence is controlled by CD154-CD40 interactions.

Miga AJ, Masters SR, Durell BG, Gonzalez M, Jenkins MK, Maliszewski C, Kikutani H, Wade WF, Noelle RJ.

Eur J Immunol. 2001 Mar;31(3):959-65.

PMID:
11241301
15.

Abnormal germinal center reactions in systemic lupus erythematosus demonstrated by blockade of CD154-CD40 interactions.

Grammer AC, Slota R, Fischer R, Gur H, Girschick H, Yarboro C, Illei GG, Lipsky PE.

J Clin Invest. 2003 Nov;112(10):1506-20. Erratum in: J Clin Invest. 2007 Mar;117(3):835.

16.
17.

Regulatory B cells in autoimmune diseases: how do they work?

Lemoine S, Morva A, Youinou P, Jamin C.

Ann N Y Acad Sci. 2009 Sep;1173:260-7. doi: 10.1111/j.1749-6632.2009.04651.x.

PMID:
19758160
18.

Prospects for CD40-directed experimental therapy of human cancer.

Tong AW, Stone MJ.

Cancer Gene Ther. 2003 Jan;10(1):1-13. Review.

PMID:
12489023
19.

CD40 signaling and autoimmunity.

Cheng G, Schoenberger SP.

Curr Dir Autoimmun. 2002;5:51-61. Review. No abstract available.

PMID:
11826760
20.

Galectin-9 controls CD40 signaling through a Tim-3 independent mechanism and redirects the cytokine profile of pathogenic T cells in autoimmunity.

Vaitaitis GM, Wagner DH Jr.

PLoS One. 2012;7(6):e38708. doi: 10.1371/journal.pone.0038708. Epub 2012 Jun 7.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk